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1. INTRODUCTION {#cas14370-sec-0001}
===============

Gastric cancer is the second leading cause of cancer‐related deaths in the world, accounting for approximately 783 000 deaths in 2018.[^1^](#cas14370-bib-0001){ref-type="ref"} The infectious agents, including the bacterium *Helicobacter pylori* [^2^](#cas14370-bib-0002){ref-type="ref"}, [^3^](#cas14370-bib-0003){ref-type="ref"} and EBV,[^4^](#cas14370-bib-0004){ref-type="ref"}, [^5^](#cas14370-bib-0005){ref-type="ref"} are the major pathogens of GC. As a human oncogenic virus, EBV has been identified in various malignant diseases, including endemic Burkitt lymphoma, nasopharyngeal carcinoma, approximately 50% of Hodgkin's disease, and 7%‐16% of GC.[^4^](#cas14370-bib-0004){ref-type="ref"}, [^6^](#cas14370-bib-0006){ref-type="ref"}, [^7^](#cas14370-bib-0007){ref-type="ref"} Due to the particular molecular subtypes in GC, EBV infection status provided us an independent classification that not only determined patient stratication, but revealed unique epigenetic phenotype and somatic genomic alterations.[^8^](#cas14370-bib-0008){ref-type="ref"} Since the publication of the EBV genome sequence in 1984,[^9^](#cas14370-bib-0009){ref-type="ref"} the molecular analysis of the virus allowed us to elucidate the mechanisms of action of the viral proteins that contribute to tumorigenesis in EBV^+^ GC.[^10^](#cas14370-bib-0010){ref-type="ref"}

A unique and characteristic feature of EBV is its capability to establish distinct latent gene expression patterns in vivo and in cultured cells (named latency type I, II, and III) in resting and proliferating cells. Epstein‐Barr virus‐positive GC, as well as Burkitt lymphoma, belong to latency I, in which the expression of viral latent genes is the most severely restricted to EBNA1, EBER, LMP2A, and *Bam*HI A rightward transcripts.[^11^](#cas14370-bib-0011){ref-type="ref"} Oncogenic functions of these viral transcripts have been studied to elucidate the tumorigenic mechanism of EBV‐associated cancer. Epstein‐Barr virus‐encoded small RNAs have been reported to contribute to tumorigenesis of GC through activation of growth factors such as insulin like growth factor 1.[^12^](#cas14370-bib-0012){ref-type="ref"} Expression of LMP2A might also facilitate cell survival by inhibiting p53 activity and TGF‐β‐associated cellular apoptosis.[^11^](#cas14370-bib-0011){ref-type="ref"} Another viral protein, EBNA1, has an important role to maintain episomal form of the EBV genome binding to the host chromosome during latent infection.

Although these functions of viral factors might partly contribute to tumorigenesis in EBV^+^ malignancies, other molecular aberrations, eg genomic and epigenomic aberrations, in host cells need to be elucidated. We have previously reported that EBV^+^ GC showed extensively high DNA methylation phenotype at gene promoter regions and abundant TSGs, eg *p16*, are repressed by the aberrant promoter hypermethylation.[^13^](#cas14370-bib-0013){ref-type="ref"}, [^14^](#cas14370-bib-0014){ref-type="ref"} We also found that in vitro EBV infection in gastric epithelial cells introduces extensive DNA hypermethylation resembling the hypermethylation phenotype of clinical EBV^+^ GC tissue samples. Although this unique DNA methylation phenotype was reportedly confirmed in EBV^+^ GC through comprehensive analyses of GC by TCGA, epigenetic aberrations have been considered important for EBV^+^ GC tumorigenesis in addition to genetic alteration, eg *PIK3CA* mutation and *PD‐L1/2* overexpression.[^8^](#cas14370-bib-0008){ref-type="ref"}, [^15^](#cas14370-bib-0015){ref-type="ref"}

Other than gene repression by aberrant DNA methylation, gene activation by aberrant enhancers is known as an epigenetic driver of many other types of cancer.[^16^](#cas14370-bib-0016){ref-type="ref"}, [^17^](#cas14370-bib-0017){ref-type="ref"} It is also reported that mutations in enhancers or enhancer‐binding TFs could cooperate with DNA methylation to aberrantly activate or repress neighboring genes and provoke cancer.[^16^](#cas14370-bib-0016){ref-type="ref"}, [^18^](#cas14370-bib-0018){ref-type="ref"} In EBV^+^ GC, we preliminarily reported aberrant activation and repression at enhancer regions as well as promoter regions;[^19^](#cas14370-bib-0019){ref-type="ref"}, [^20^](#cas14370-bib-0020){ref-type="ref"} however, the mechanisms to induce epigenetic activation during EBV infection in gastric epithelial cells is yet to be fully investigated.

To identify factors that can induce aberrant enhancer activation during EBV infection, we undertook comprehensive analyses of histone modification and open chromatin regions to predict their putative binding elements. We identified that ATF3, which is activated by various environmental stresses and reportedly has dual functions as a TSG or an oncogene in several types of cancer,[^21^](#cas14370-bib-0021){ref-type="ref"}, [^22^](#cas14370-bib-0022){ref-type="ref"} promoted proliferation in EBV^+^ gastric cells. This investigation could provide insights into the epigenomic activations in enhancer regions, and thus tumorigenesis, by EBV infection in gastric epithelial cells.

2. MATERIAL AND METHODS {#cas14370-sec-0002}
=======================

2.1. Cell culture {#cas14370-sec-0003}
-----------------

The SNU719 EBV^+^ GC cell line was obtained from the Korean Cell Line Bank, and NCC24 from Creative Bioarray. The MKN7 EBV^−^ GC cell line (MKN7_WT), which shows a low DNA methylation epigenotype,[^13^](#cas14370-bib-0013){ref-type="ref"} was purchased from Riken BioResource Center Cell Bank. GES1 is a normal fetal gastric epithelial cell line immortalized with SV40 (Beijing Institute for Cancer Research).[^23^](#cas14370-bib-0023){ref-type="ref"} Cells were cultured in RPMI‐1640 medium supplemented with 10% FBS and penicillin/streptomycin. MKN7 and GES1 cells were infected with recombinant EBV using the Akata system to establish EBV‐infected MKN7 cells (MKN7_EB) as previously reported.[^13^](#cas14370-bib-0013){ref-type="ref"}, [^24^](#cas14370-bib-0024){ref-type="ref"} The study design was approved by the institutional review board of Chiba University.

2.2. Chromatin immunoprecipitation‐seq and FAIRE‐seq analysis {#cas14370-sec-0004}
-------------------------------------------------------------

Chromatin immunoprecipitation assays for histone modifications and FAIRE assays for open chromatin regions were carried out as previously reported.[^25^](#cas14370-bib-0025){ref-type="ref"} For ChIP assays for ATF3 binding regions, cells were treated with 30 μM CDDP for 48 hours to induce ATF3 expression. Approximately 1 × 10^7^ cells were cross‐linked with 1% formaldehyde for 10 minutes at room temperature and formaldehyde was quenched by addition of 2.5 M glycine to a final concentration of 0.125 M. Cross‐linked chromatin was sonicated to a size of 0.2‐1 kb using an ultrasonic disruptor (Branson Digital Sonifier). A total of 15 μg anti‐ATF3 Ab (sc‐188 X, rabbit mAb; Santa Cruz Biotechnology) and 20 μL Protein G Sepharose beads were mixed in IP dilution buffer and incubated for 6 hours at 4°C. After washing with IP dilution buffer, Ab‐binding beads were added to the sonicated chromatin sample and incubated overnight at 4°C. Beads were washed and chromatin was eluted, followed by reversal of the cross‐linking and DNA purification. Chromatin‐immunoprecipitated DNA was dissolved in EB buffer (Qiagen). Libraries were constructed by using NEBNext ChIP‐seq Library Prep Reagent Set for Illumina (NEB) according to the manufacturer's instructions. The sequencing libraries were quantified by Bioanalyzer (Agilent) and sequenced at a concentration of 4 pM on an Illumina Hiseq (Illumina).

Sequenced reads in ChIP‐seq and FAIRE‐seq experiments were mapped to the UCSC human genome (hg19) using bowtie 2. Duplicated reads were removed with Picard tools. Peak calling and motif analyses were carried out by using HOMER software ([bib26://homer.salk.edu/homer/index.html)](bib26://homer.salk.edu/homer/index.html)),[^26^](#cas14370-bib-0026){ref-type="ref"} which was also used to count reads for each signal. Peak annotation to the nearest genes was undertaken by using bedtools. Peak heatmaps were produced with the use of HOMER and TreeView for enrichment calculation and visualization.

2.3. RNA sequencing {#cas14370-sec-0005}
-------------------

RNA was extracted by using the RNeasy Mini Kit (Qiagen) following the manufacturer's protocol and treated with DNaseI (Qiagen). Libraries for RNA‐seq were prepared using the TruSeq Stranded mRNA Sample Prep Kit (Illumina), following the manufacturer's protocol. Deep sequencing was carried out on the Illumina HiSeq 1500 or NextSeq 500 platform using the TruSeq Rapid SBS Kit (Illumina) in 50‐base single‐end mode according to the manufacturer's protocol. Sequenced reads from the RNA‐seq experiment were aligned by using HISAT2, and Cufflinks was used for transcript assembly. Gene expression levels were expressed as fragments per kilobase of exon per million mapped sequence reads.

2.4. Cancer hallmark analysis {#cas14370-sec-0006}
-----------------------------

The ATF3 target genes identified were compared with GO categories related with cancer hallmarks.[^27^](#cas14370-bib-0027){ref-type="ref"} The GO categories used for the analysis of cancer hallmarks are shown in Table [S1](#cas14370-sup-0001){ref-type="supplementary-material"}.

2.5. Knockdown by shRNA {#cas14370-sec-0007}
-----------------------

To knock down *ATF3*, double‐stranded oligonucleotide DNA encoding shRNA against *ATF3* was cloned into the pLKO.1 vector between *Eco*RI and *Age*I sites, as previously described.[^28^](#cas14370-bib-0028){ref-type="ref"} Oligonucleotide sequences to ligate in the vector for construction of shATF3 and shNON are as follows, where 21‐mer target sequences are underlined: shATF3, CCGG [GCTGAACTGAAGGCTCAGATT]{.ul} CTCGAG [AATCTGAGCCTTCAGTTCAGC]{.ul} TTTTTG and AATTCAAAAA [GCTGAACTGAAGGCTCAGATT]{.ul} CTCGAG [AATCTGAGCCTTCAGTTCAGC]{.ul}; and shNON CCGG [CAACAAGATGAAGAGCACCAA]{.ul} CTCGAG [TTGGTGCTCTTCATCTTGTTG]{.ul} TTTTT and AATTCAAAAA [CAACAAGATGAAGAGCACCAA]{.ul} CTCGAG [TTGGTGCTCTTCATCTTGTTG]{.ul}. Viral packaging for shRNA retrovirus vectors was undertaken using 293T cells and FuGENE 6 (Promega), and medium containing the virus was collected 48 hours after transfection.

2.6. Overexpression of latent EBV factors {#cas14370-sec-0008}
-----------------------------------------

Latent viral factors, BARF, EBER1, EBNA1, and LMP2A, were previously constructed in pcDNA3 vector.[^13^](#cas14370-bib-0013){ref-type="ref"} Each vector or mock vector was introduced in MKN7 cells using FuGene6, and gene expression was analyzed by RNA‐seq as above.

2.7. Overexpression of mutant EBNA1 {#cas14370-sec-0009}
-----------------------------------

Mutant ENBA1 to act as a dominant‐negative inhibitor of EBNA1 was constructed according to the previous report.[^29^](#cas14370-bib-0029){ref-type="ref"} Mutant EBNA1 fused by mCherry fluorescent protein at the C‐terminal region (mtEBNA1‐mCherry) was inserted into the modified pcDNA5 vector.[^28^](#cas14370-bib-0028){ref-type="ref"} Mock vector with only mCherry inserted was also constructed and used as a control. Vectors with mtEBNA1‐mCherry or mCherry were transfected in MKN7_EB cells by Lipofectamine 3000. On day 7, strongly red‐colored cells caused by mCherry were sorted by a cell sorter HS800 (Sony). Decrease of EBV copy numbers was examined by qPCR.

2.8. Real‐time qPCR {#cas14370-sec-0010}
-------------------

Real‐time qPCR was undertaken using SYBR Green and CFX96 Touch Real‐Time PCR (Bio‐Rad Laboratories). The quantity of genomic DNA in a sample was estimated by comparisons with standard samples that contained 10^1^ to 10^6^ gene copies, as previously described.[^13^](#cas14370-bib-0013){ref-type="ref"} The quantity of EBV genome was normalized to that of the *HBB* region in the human genome. Primers for the EBV genome are TCGTACATCT CCAGGCGACA CT and CATACAACCA CTGGCGATCC CC. Primers for HBB are CAGGGTGAGG TCTAAGTGAT GA and TTGAAGTCCA ACTCCTAAGC CA.

2.9. Real‐time qPCR {#cas14370-sec-0011}
-------------------

cDNA was prepared from 1 μg total RNA using SuperScript III Reverse Transcriptase (Thermo Fisher). Real‐time qPCR was undertaken as above, using cDNA as a template, and the quantity of mRNA for each gene in a sample was estimated by comparisons with standard samples that contained 10^1^ to 10^6^ gene copies.[^13^](#cas14370-bib-0013){ref-type="ref"} The expression level of *ATF3* was normalized to that of *B2M*. The PCR primers for *ATF3* are GGATGTCCTC TGCGCTGGAA TC and TCCTTTCATC TTCTTCAGGG GC. Primers for *B2M* are GATGAGTATG CCTGCCGTGT and CTGCTTACAT GTCTCGATCC CA.

2.10. Western blot analysis {#cas14370-sec-0012}
---------------------------

Cells were lysed in a lysis buffer containing 62.5 mM Tris‐HCl (pH6.8), 2.3% SDS, 10% glycerol, 0.2% bromophenol blue for whole cell or 10 mM Tris‐HCl (pH 7.4), 10 mM NaCl, 2.5 mM MgCl~2~, 1 mM EDTA, 1 mM EGTA, 0.5% NP40, and proteinase inhibitor cocktails (Roche) for cytoplasm and nuclear fraction. The following primary Abs were used: anti‐ATF3 (sc‐188 X; Santa Cruz Biotechnology for whole cell; or \#33593, rabbit mAb; Cell Signaling Technology for cytoplasm and nuclear fraction), anti‐Actin (MA5‐11869, mouse mAb; Invitrogen), anti‐Lamin A (NA934V, rabbit polyclonal; GE Healthcare), and anti‐α‐tubulin (sc‐5286, mouse mAb; Santa Cruz Biotechnology). Protein‐blotted membranes were incubated with Abs using Can Get Signal Immunoreaction Enhancer Solution (Toyobo) at 4°C overnight for the primary Abs, and at room temperature for 1 hour for secondary Abs, followed by visualization using the ECL prime system (GE Healthcare). The protein signals were detected using a Luminescent Image Analyzer LAS‐3000 (Fujifilm).

2.11. Cell growth assay {#cas14370-sec-0013}
-----------------------

Cells were seeded into 6 wells of 96‐well plates at 2000 cells per well in 200 μL culture medium. After an appropriate period of culturing, WST‐8 reagent (Dojindo) was added to each well, followed by incubation for 4 hours at 37°C in 5% CO~2~. Absorbance at 450 nm was measured using a SpectraMax PLUS 384 microplate reader (Molecular Devices).

2.12. Caspase 3/7 apoptosis staining {#cas14370-sec-0014}
------------------------------------

Analysis of apoptosis staining was undertaken using CellEvent Caspase‐3/7 Green Detection Reagent (Caspase 3/7) (Invitrogen). The apoptotic cells were imaged using a BZ‐X710 microscope (Keyence). Imaged data were processed and quantified using ImageJ.[^30^](#cas14370-bib-0030){ref-type="ref"}

2.13. Statistical analysis {#cas14370-sec-0015}
--------------------------

The *P* values for expression analysis were obtained using paired *t* test to evaluate differences between 2 groups, with *P* less than .05 considered statistically significant. Gene Ontology analysis was undertaken by using Metascape (<http://metascape.org/gp/index.html#/main/step1)>.[^31^](#cas14370-bib-0031){ref-type="ref"} Gene set enrichment analysis was undertaken using GSEA software version 4.0.3 (<http://software.broadinstitute.org/gsea/index.jsp)>.[^32^](#cas14370-bib-0032){ref-type="ref"}

3. RESULTS {#cas14370-sec-0016}
==========

3.1. Detection of activated enhancers in EBV‐infected MKN7 cells {#cas14370-sec-0017}
----------------------------------------------------------------

We undertook a FAIRE‐seq analysis in MKN7_EB to detect open chromatin regions in gene promoters and enhancers. Promoter regions were defined by H3K4me3 peaks, and enhancer regions were defined by H3K4me1 peaks without H3K4me3 signal (Figure [1A](#cas14370-fig-0001){ref-type="fig"},[B](#cas14370-fig-0001){ref-type="fig"}). We identified a total of 52 850 FAIRE peaks in MKN7_EB, including 13 209 peaks (25%) in promoters and 19 992 peaks (38%) in enhancers. While the majority of FAIRE peaks were distributed to enhancer regions, 10 260 (51%) of those showed an increase of H3K27ac signals and thus were activated, 4523 (23%) showed no change in H3K27ac signals, and 5209 (26%) showed a decrease of H3K27ac signals and thus were inactivated (Figure [1C](#cas14370-fig-0001){ref-type="fig"}).

![Detection of activated enhancers in Epstein‐Barr virus (EBV)‐infected MKN7 cells, MKN7_EB *WT*, MKN7_WT *EB*, and MKN7_EB. A, Representative formaldehyde‐assisted isolation of regulatory elements (FAIRE) signals on promoter and enhancer regions. Promoter and enhancer regions were defined as H3K4me3 peaks, and as H3K4me1 peaks without H3K4me3 signal, respectively. B, Distribution of FAIRE peaks. Among 52 850 FAIRE peaks in MKN7_EB, 13 209 and 19 992 peaks were detected in promoter regions and enhancer regions, respectively. C, Alteration of H3K27ac signals around 19 992 FAIRE peaks on enhancer regions. Heatmaps represent read densities of FAIRE, H3K4me1, H3K4me3 and H3K27ac within the ±5‐kb region from the FAIRE peak center (left). Histograms indicate the average read per million (RPM) reads of H3K27ac within ±5‐kb regions from the FAIRE peak center (right). The 10 260 and 5209 regions showed increase and decrease of the H3K27ac signals, respectively](CAS-111-1818-g001){#cas14370-fig-0001}

Using the top 3000 regions showing higher H3K27ac signals among 10 260 activated enhancers, motif analysis was used to search for candidate TFs binding to these regions (Figure [2A](#cas14370-fig-0002){ref-type="fig"}). The top 5 significant motifs (*P* values ranging 1 × 10^−55^ to 1 × 10^‐819^) were detected, and candidate TFs were identified to match those significant motifs. Expression levels of genes near the motifs were analyzed by RNA‐seq and compared between MKN7_WT and MKN7_EB (Figure [2B](#cas14370-fig-0002){ref-type="fig"}). Significant upregulation of these neighboring genes was confirmed in MKN7_EB, suggesting that the activated enhancers could function in upregulation of the nearby genes. Among the candidate TFs, *ATF3*,*TEAD2*, and *RUNX3* were upregulated more than 2‐fold in MKN7_EB in mRNA levels (Figure [2C](#cas14370-fig-0002){ref-type="fig"}). When EBV was infected in GES1 normal gastric epithelial cells, upregulation of *ATF3* was confirmed, but *TEAD2* and *RUNX3* were not upregulated (Figure [2D](#cas14370-fig-0002){ref-type="fig"}). We therefore focused on ATF3, and upregulation of ATF3 in MKN7_EB was detected in not only mRNA levels but also protein levels (Figure [2E](#cas14370-fig-0002){ref-type="fig"}).

![Detection of activating transcription factor 3 (ATF3) as a candidate TF. A, Motif analysis for activated enhancer regions. Among 10 260 activated enhancer regions, the top 3000 regions with highly expressed H3K27ac signal were extracted and subjected to de novo motif analysis. Top 5 significant motifs and candidate TFs, ATF3, JUN, JUNB, FOSL2, and BATF, are shown. B, Expression of genes neighboring the top 5 motifs. Neighboring genes were significantly upregulated in Epstein‐Barr virus (EBV)‐infected MKN7 cells (MKN7_EB). C, Relative expression levels of candidate TFs in MKN7_EB. While *ATF3*, *TEAD2*, and *RUNX3* were clearly upregulated in MKN7_EB, other candidate TFs were not. D, Expression of genes in EBV‐infected GES1 cells. *ATF3* was confirmed to be upregulated after EBV infection, whereas *TEAD2* and *RUNX3* were not. E, ATF3 protein level in cytoplasm and nucleus. Western blot showed ATF3 localized in nucleus, and expressed at higher levels in MKN7_EB cells. Open and closed boxes indicate relative ratio of the intensity of ATF3 to that of lamin A in the nucleus in MKN7_WT and MKN7_EB cells, respectively (n = 3). Values are shown as the mean ± SD](CAS-111-1818-g002){#cas14370-fig-0002}

To gain insight into the viral factors that might upregulate ATF3 expression in host cells, viral factors including BARF, EBER1, EBNA1, and LMP2A, which are known to be expressed in latent infection of EBV, were overexpressed in MKN7 cells, and RNA‐seq was carried out. Activating transcription factor 3 was found to be upregulated the most by EBNA1 overexpression, and relative upregulation by more than 1.5‐fold was also detected by EBER1or LMP2A overexpression (Figure [3A](#cas14370-fig-0003){ref-type="fig"}). Previous ChIP‐seq analysis for EBNA1 target regions[^33^](#cas14370-bib-0033){ref-type="ref"}, [^34^](#cas14370-bib-0034){ref-type="ref"} showed that EBNA1 can bind to an enhancer region upstream of *ATF3*. When mutant EBNA1 was overexpressed in MKN7_EB, the copy number of the EBV genome was confirmed to be decreased, resulting in a considerable decrease of *ATF3* expression level (Figure [3C](#cas14370-fig-0003){ref-type="fig"}). These results indicate that ATF3 could be upregulated, at least partly, by expression of EBV factors, eg EBNA1.

![Upregulation of activating transcription factor 3 (ATF3) by Epstein‐Barr virus (EBV) factors. A, Relative expression of *ATF3* in conditions of overexpression of EBV factors. Each EBV factor, known to express in latent infection in EBV^+^ gastric cancer, was overexpressed in MKN7 cells and expression level of *ATF3* was analyzed by RNA sequencing (RNA‐seq). *ATF3* was most upregulated by overexpression of EBV‐determined nuclear antigen 1 (EBNA1), and \>1.5‐fold by EBV‐encoded small RNA 1 (EBER1) and latent membrane protein 2A (LMP2A). B, EBNA1 target region for *ATF3*. Previous ChIP‐seq data for EBNA1 binding regions showed that EBNA1 could bind to an enhancer region upstream of *ATF3*. C, EBNA1 inhibitor. Overexpression of mutant EBNA1, known as EBNA1 inhibitor, in MKN7_EB cells resulted in decrease of the copy number of EBV genome and *ATF3* expression](CAS-111-1818-g003){#cas14370-fig-0003}

3.2. Identification of possible ATF3 binding sites by ChIP‐seq {#cas14370-sec-0018}
--------------------------------------------------------------

To identify target regions of ATF3 genome‐wide, ChIP‐seq using anti‐ATF3 Ab was used against ATF3 binding sites (Figure [4](#cas14370-fig-0004){ref-type="fig"}). As ATF3 overexpression using pcDNA5 expression vector in MKN7 led to more than 100‐fold upregulation of ATF3 and cell death at 36 hours, ATF3 upregulation was induced in MKN7 cells by exposure to 30 μM CDDP instead. As ATF3 expression was increased in a time‐dependent manner up to 48 hours (Figure [4A](#cas14370-fig-0004){ref-type="fig"}), ChIP‐seq analysis of possible ATF3 binding sites was carried out using MKN7 cells at 48 hours after CDDP exposure (Figure [4B](#cas14370-fig-0004){ref-type="fig"},[C](#cas14370-fig-0004){ref-type="fig"}). Among a total of 3345 ATF3 peaks defined by ChIP‐seq analysis, 1339 peaks were distributed to enhancer regions, and 590 of those showed increase of H3K27ac signals and thus were activated (Figure [4D](#cas14370-fig-0004){ref-type="fig"}). Expression levels of 659 genes neighboring ATF3 peaks on the 590 activated enhancers were significantly increased (*P* = 1.5 × 10^‐6^).

![Identification of possible activating transcription factor 3 (ATF3) binding sites. A, ATF3 induction in MKN7 cells by exposure to cisplatin (CDDP). To analyze the possible ATF3 binding site in MKN7 cells, ATF3 was induced by exposure to 30 μM CDDP for 48 h. B, Representative ATF3 signals. Possible ATF3 binding sites were analyzed by ChIP sequencing (ChIP‐seq) in ATF3‐induced MKN7 cells at 48 h after CDDP treatment. C, Distribution of ATF3 peaks. Among 3345 ATF3 peaks detected, 715 and 1339 peaks were distributed to promoter and enhancer regions, respectively. D, Heatmaps of read densities in ATF3‐bound enhancer regions. Read densities of ChIP‐seq for ATF3, H3K4me1, H3K4me3, and H3K27ac, and those for formaldehyde‐assisted isolation of regulatory elements (FAIRE)‐seq within ±5‐kb regions from the ATF3 peak center, are shown (left). Histogram indicated the average read per million (RPM) reads of H3K27ac (right). The 590 and 406 regions showed increase and decrease of the H3K27ac signals, respectively. Expression levels of 659 and 510 genes neighboring ATF3 peaks in the 590 activated or 406 inactivated enhancer regions were significantly increased (*P* = 1.5 × 10^−6^), or decreased (*P* = 3.7 × 10^−7^), respectively. Values are shown as the mean ± SEM](CAS-111-1818-g004){#cas14370-fig-0004}

3.3. Identification of ATF3 target genes {#cas14370-sec-0019}
----------------------------------------

As the possible ATF3 binding sites might include regions targeted specifically in the condition of CDDP exposure, ATF3 was knocked down in MKN7_EB cells by a shATF3 to screen genes targeted by ATF3 in EBV‐infected cells. Repression of ATF3 was confirmed by western blot analysis (Figure [5A](#cas14370-fig-0005){ref-type="fig"}). Gene expression alteration by knockdown of ATF3 was analyzed by RNA‐seq. Among the 659 genes neighboring possible ATF3 binding sites at active enhancer regions, we identified 96 genes downregulated by ATF3 knockdown in MKN7_EB cells, namely ATF3 target genes (Figure [5B](#cas14370-fig-0005){ref-type="fig"}). By GSEA, it was confirmed that these ATF3 target genes were shown to be significantly enriched in highly expressed genes in MKN7_EB compared with MKN7_WT (NES = 1.88, *P* \< .001) (Figure [5C](#cas14370-fig-0005){ref-type="fig"}). The top 30 ATF3 target genes that showed high expression in MKN7_EB cells in the GSEA were found to be considerably related with cancer hallmarks, such as evading growth suppressors, sustaining proliferative signaling, and resisting cell death (Figure [5D](#cas14370-fig-0005){ref-type="fig"}).

![Identification of activating transcription factor 3 (ATF3) target genes. A, Knockdown of ATF3 in Epstein‐Barr virus (EBV)‐infected MKN7 (MKN7_EB) cells. ATF3 was knocked down by shRNA lentivirus targeting *ATF3* (shATF3). Western blot analysis showed marked decrease of ATF3 expression in the nucleus. Right, comparison of ratios of the intensity of ATF3 to that of lamin A in nucleus (n = 3). Values are shown as the mean ± SD. B, RNA sequencing analysis of gene expression alterations by knockdown of ATF3. Among the 659 genes neighboring possible peaks bound by ATF3, 96 genes were downregulated in MKN7_EB when ATF3 was knocked down (red dots). C, Gene set enrichment analysis (GSEA) for the 96 ATF3 target genes. The 96 ATF3 target genes were significantly enriched in the genes highly expressed in MKN7_EB (normalized enrichment score \[NES\] = 1.88, *P* \< .001). D, Relationship with cancer hallmarks. Among the 96 ATF3 target genes, the top 30 genes showing higher expression in MKN7_EB in GSEA were extracted. They were frequently related with cancer hallmarks, such as evading growth suppressors, sustaining proliferative signaling, and resisting cell death. FPKM, fragments per kilobase of exon per million mapped sequence reads; shNON, control nontarget shRNA](CAS-111-1818-g005){#cas14370-fig-0005}

3.4. Knockdown of ATF3 in EBV^+^ GC cell lines NCC24 and SNU719 {#cas14370-sec-0020}
---------------------------------------------------------------

Additionally, ATF3 was knocked down by shATF3 in 2 EBV^+^ GC cell lines NCC24 and SNU719, and repression of ATF3 was confirmed by western blot (Figure [6](#cas14370-fig-0006){ref-type="fig"}). RNA sequencing was used to analyze gene expression alteration. Gene set enrichment analysis showed that the 96 ATF3 target genes were significantly enriched in genes downregulated by knockdown of ATF3, in both NCC24 and SNU719 cells, compared with shNON control cells (Figure [6A‐D](#cas14370-fig-0006){ref-type="fig"}). We analyzed the cellular growth of ATF3 knocked‐down cells by WST‐8 assay (Figure [6E](#cas14370-fig-0006){ref-type="fig"}). Significant repression of cellular growth was detected in MKN7_EB, NCC24, and SNU719 cells when ATF3 was knocked down. Caspase 3/7 activity was analyzed to detect apoptotic cells, and apoptosis was observed significantly frequently in MKN7_EB, NCC24, and SNU719 cells when ATF3 was knocked down (Figure [6F](#cas14370-fig-0006){ref-type="fig"}).

![Knockdown of activating transcription factor 3 (ATF3) and repression of cellular growth. A, Knockdown of ATF3 in NCC24 cells. ATF3 was knocked down in Epstein‐Barr virus (EBV)^+^ gastric cancer (GC) cell line NCC24 by shRNA lentivirus targeting *ATF3* (shATF3). Right, ratio of the intensity of ATF3 to that of lamin A in nucleus (n = 3). Values are shown as the mean ± SD. B, Gene set enrichment analysis (GSEA) for the 96 ATF3 target genes in NCC24 cells. ATF3 target genes were significantly downregulated in NCC24 cells with ATF3 knockdown. C, Knockdown of ATF3 in EBV^+^ GC cell line SNU719. D, GSEA of the 96 ATF3 target genes in SNU719 cells. E, Repression of cellular growth of MKN7_EB, NCC24, and SNU719. Cellular growth was measured by WST‐8 assay for 5 days (n = 6), and relative growth is shown. Knockdown of ATF3 led to decrease of cellular growth in all the EBV^+^ cells analyzed. F, Caspase 3/7 assay. Apoptotic cells were counted by caspase 3/7 activity (green). Frequency of apoptotic cells was increased by knockdown of ATF3 in all the EBV^+^ cells analyzed. Values are shown as the mean ± SD (n = 3). NES, normalized enrichment score; shNON, control nontarget shRNA](CAS-111-1818-g006){#cas14370-fig-0006}

4. DISCUSSION {#cas14370-sec-0021}
=============

Through integrated analyses on alterations of transcriptome, histone modification, and open chromatin status, we here identified ATF3 as a critical transcriptional activator after EBV infection in gastric cells. We undertook screening of putative TF binding to activated enhancer regions that are predicted by motif analysis and refined by gene expression analysis. ATF3 was identified as a candidate TF that is upregulated by EBV infection and induces aberrant enhancer activation. Expression of viral factors might be the cause of upregulated ATF3 expression, at least partly, and the effect of ATF3 expression on cellular proliferation was confirmed, suggesting a tumorigenic role of aberrant enhancer activation by ATF3 upregulation.

ATF3 is known to play different roles depending on various interacting partners. It is activated by a variety of environmental stress signals and is associated with the pathogenesis of various diseases including cancer, cardiac hypertrophy, and infection.[^35^](#cas14370-bib-0035){ref-type="ref"} In cancer, reciprocal functions of ATF3 as either an oncogene or a TSG have been reported, depending on the condition of the cell. It reportedly promotes apoptosis of human cancer cells, such as T‐cell lymphoma, multiple myeloma, blood, lung, prostate, and colon cancer cells,[^36^](#cas14370-bib-0036){ref-type="ref"}, [^37^](#cas14370-bib-0037){ref-type="ref"}, [^38^](#cas14370-bib-0038){ref-type="ref"}, [^39^](#cas14370-bib-0039){ref-type="ref"} and overexpression of ATF3 reportedly promotes the metastasis of prostate and breast cancer.[^40^](#cas14370-bib-0040){ref-type="ref"}, [^41^](#cas14370-bib-0041){ref-type="ref"} As an oncogene, TGF‐β, p53, and Wnt/β‐catenin signaling pathways are the known factors to activate ATF3, leading to the expression of downstream factors, eg MMP13, Snail, Slug, and Twist, which are key regulators of epithelial‐mesenchymal transition and metastasis.[^42^](#cas14370-bib-0042){ref-type="ref"} ATF3 was also reported to promote Runx2 expression in metastatic breast cancer cells, aiding bone metastasis of tumor cells.[^43^](#cas14370-bib-0043){ref-type="ref"} In this study, ATF3 was found to be upregulated by EBV infection through expression of EBV factors, eg EBNA1, EBER1, and LMP2A, and downregulation of ATF3 was confirmed when the copy number of the EBV genome was decreased in MKN7_EB due to overexpression of mutant EBNA1. Knockdown experiments of ATF3 showed that ATF3 has an oncogenic role to promote proliferation in EBV‐infected gastric cells. Downstream targets of ATF3 were also shown to correlate with hallmarks of cancer, which might contribute to EBV^+^ GC progression.

The sequence‐specific DNA binding protein EBNA1 binds with high affinity to 3 well‐characterized sites in the viral genome that are important for maintenance of the episomal viral genome, DNA replication, and viral gene regulation. Several papers reported that there exist numerous EBNA1 binding sites in the host genome and that EBNA1 binds to these sites to activate the expression of neighboring host genes.[^33^](#cas14370-bib-0033){ref-type="ref"}, [^34^](#cas14370-bib-0034){ref-type="ref"} It has been reported that EBNA1 activates many other host genes directly, which can function in various pathways related to cancer proliferation, including several cytokine pathways (IL‐18, IL‐6, IL‐12, and IL‐2), the p38 MAPK and MAP3K1 network in B cells,[^33^](#cas14370-bib-0033){ref-type="ref"}, [^34^](#cas14370-bib-0034){ref-type="ref"} the activator protein 1 (AP1) transcription factor pathway in nasopharyngeal carcinoma cells,[^44^](#cas14370-bib-0044){ref-type="ref"} and signal transducer and activator of transcription 1 (STAT1) in carcinoma and B‐lymphoma cells,[^45^](#cas14370-bib-0045){ref-type="ref"}, [^46^](#cas14370-bib-0046){ref-type="ref"} although ATF3 had not been identified as an EBNA1 downstream target. This study showed that EBNA1 might be an EBV factor to potentially induce upregulation of ATF3, and thus promote proliferation in GC cells; mechanisms to activate ATF3 expression, eg function analysis of EBNA1 binding site nearby ATF3 as an enhancer, should be further investigated.

Previous comprehensive analyses of GC by us or TCGA revealed that EBV^+^ GC shows a unique DNA hypermethylation phenotype that is the most extensive hypermethylation among all the human malignancies.[^8^](#cas14370-bib-0008){ref-type="ref"}, [^13^](#cas14370-bib-0013){ref-type="ref"} Distinct mutations of genes, eg *PIK3CA* and *ARID1A*, are also observed in EBV^+^ GC.[^8^](#cas14370-bib-0008){ref-type="ref"} Most of these aberrations are related with repression of tumor suppressive functions in gastric epithelial cells, and viral proteins also mainly function to repress tumor suppressive functions, except EBERs that reportedly promote tumor progression through activation of growth factors. Recently, aberrant enhancer activation has been reported in many types of cancer to promote oncogene activation and is reportedly caused by genomic aberrations such as amplification or translocation, or activation of oncogenic master regulators in various cancers. Whereas enhancer activation in EBV^+^ GC has been reported in only a few published works, we here found that ATF3 is upregulated and contributes to enhancer activation in EBV‐infected gastric cells.

In summary, we undertook integrated analyses on alterations of the transcriptome and epigenome during EBV infection in gastric epithelial cells and identified upregulation of ATF3 that could contribute to aberrant enhancer activation in EBV^+^ GC and enhance proliferation of gastric cells by EBV infection.
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